WASHINGTON, D.C. (March 15, 2022) – A new Ipsos/PhRMA poll reveals that Americans do not support government “negotiation” of drug prices once they learn about the tradeoffs, particularly among those who would be most impacted – seniors and patients taking prescription medicines. Specifically, just 10% of seniors support government “negotiation” when presented with potential consequences of the proposal, including the negative impact on access to and future development of new medicines and treatments.
“Seniors and patients are clear. They do not support so-called government ‘negotiation’ when they learn it will sacrifice access and future innovation. Every country that has price controls has experienced these trade-offs, and non-partisan experts warn the same thing could happen in America,” said Debra DeShong, Executive Vice President for Public Affairs. “When presented with these facts, the American public rejects government price setting and instead wants Congress to focus on patient-centered solutions that improve health insurance coverage and lower out-of-pocket health care costs.”
The poll was conducted among 2,510 American adults using Ipsos’ probability based KnowledgePanel®, and it is representative of the American adult population. The margin of sampling error is plus or minus 2.2 percentage points at the 95% confidence level, for results based on the entire sample of adults. For more details on the Ipsos/PhRMA poll click here.
Learn more about our previous Ipsos/PhRMA release on health care coverage and costs here.
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Over the last decade, PhRMA member companies have more than doubled their annual investment in the search for new treatments and cures, including nearly $101 billion in 2022 alone.